<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386022</url>
  </required_header>
  <id_info>
    <org_study_id>2000-P-002498</org_study_id>
    <secondary_id>R01AG013241</secondary_id>
    <nct_id>NCT00386022</nct_id>
  </id_info>
  <brief_title>The Effects of Aging and Estrogen on the Pituitary</brief_title>
  <official_title>The Effect of Aging on the Isolated Pituitary Response to Gonadotropin Releasing Hormone at Baseline and With Low Dose Estrogen Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the effects of aging and estrogen on the brain.
      Specifically, this study will examine how the hypothalamus signals the pituitary gland to
      secrete reproductive hormones and how that changes with aging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although it is clear that loss of ovarian function plays a major role in the menopause in
      women, there is evidence from animal studies that primary age-related hypothalamic and
      pituitary changes may also contribute to reproductive aging. Complete cessation of ovarian
      function results in the loss of negative feedback of ovarian steroids and inhibin on the
      hypothalamic and pituitary components of the reproductive axis. An increase in serum levels
      of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) occurs in postmenopausal
      women with removal of negative ovarian feedback. However, levels of LH and FSH after
      menopause decline steadily as a function of age in most though not all studies.

      The current study is designed to determine: 1) whether negative feedback on LH and FSH occurs
      at the pituitary; and 2) whether there is an effect of aging on estrogen negative feedback at
      the pituitary. Younger and older postmenopausal women underwent a baseline study and a second
      identical study after a month of low dose estrogen replacement. The study protocol consisted
      of the following: 1) administration of a GnRH antagonist (Nal-Glu at 150 mg/kg that blocks
      endogenous GnRH so that the dose and interval of pituitary exposure to GnRH are precisely
      controlled; 2) beginning 8 hours following GnRH antagonist administration (at a time when LH
      had reached its nadir following GnRH receptor blockade), administration of 4 graded doses of
      GnRH (25, 75, 250 and 750 ng/kg every 2 hours with 2 hours of blood draws following each
      dose). Blood was sampled every 30 min for 4 hours before antagonist administration, every 30
      min for the following 7 hours and then every 10 min until the completion of the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study will is considered sequential as participants were studied at baseline and after one month of low-dose estrogen. Randomization refers to randomization of the order of doses of GnRH between participants.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pituitary Response to GnRH</measure>
    <time_frame>Peak hormone level within 2 hours post GnRH doses</time_frame>
    <description>Baseline LH and FSH responses to each of 4 GnRH doses - peak to nadir amplitude expressed as percent (%) change from nadir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Estrogen on Pituitary Response to GnRH</measure>
    <time_frame>Peak hormone level within 2 hours post GnRH doses</time_frame>
    <description>LH and FSH responses to each of 4 GnRH doses, expressed as change in amplitude [amp] from peak to nadir between plus estrogen and baseline conditions</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Young postmenopausal women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Older postmenopausal women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH</intervention_name>
    <description>GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol</description>
    <arm_group_label>Young postmenopausal women</arm_group_label>
    <arm_group_label>Older postmenopausal women</arm_group_label>
    <other_name>gonadotropin-releasing hormone</other_name>
    <other_name>Factryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NAL-GLU GnRH antagonist</intervention_name>
    <description>A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol</description>
    <arm_group_label>Young postmenopausal women</arm_group_label>
    <arm_group_label>Older postmenopausal women</arm_group_label>
    <other_name>GnRH antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrogen patch</intervention_name>
    <description>transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study</description>
    <arm_group_label>Young postmenopausal women</arm_group_label>
    <arm_group_label>Older postmenopausal women</arm_group_label>
    <other_name>Climara</other_name>
    <other_name>Estraderm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  45-55 or 70-80 years old

          -  History of natural menopause defined by the absence of menses for at least 12 months
             (or history of surgical menopause defined as bilateral oophorectomy) and a FSH level
             &gt;26 IU/L

          -  On no hormonal medication or herbal supplements and/or over the counter menopause
             therapy for a minimum of 2 months prior to study

          -  Normal thyroid stimulating hormone, prolactin, factor V Leiden, and complete blood
             count - Normal blood urea nitrogen and creatinine (&lt; 2 times the upper limit of
             normal)

          -  basal metabolic index â‰¤ 30

          -  Non-smokers or smoke less than 10 cigarettes/day

        Exclusion Criteria:

          -  Absolute contraindications to the use of physiologic replacement doses of estrogen,
             including a negative screening mammogram within the past 24 months

          -  History of coronary artery disease

          -  On medications thought to act centrally on the GnRH pulse generator

          -  Past history of hypersensitivity or allergy to narcotics, vancomycin, muscle
             relaxants, aspirin, and/or anaphylactic reaction(s) to other drugs

          -  Prior history of breast cancer and/or blood clots
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet E Hall, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shaw ND, Histed SN, Srouji SS, Yang J, Lee H, Hall JE. Estrogen negative feedback on gonadotropin secretion: evidence for a direct pituitary effect in women. J Clin Endocrinol Metab. 2010 Apr;95(4):1955-61. doi: 10.1210/jc.2009-2108. Epub 2010 Feb 4.</citation>
    <PMID>20133465</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaw ND, Srouji SS, Histed SN, McCurnin KE, Hall JE. Aging attenuates the pituitary response to gonadotropin-releasing hormone. J Clin Endocrinol Metab. 2009 Sep;94(9):3259-64. doi: 10.1210/jc.2009-0526. Epub 2009 Jun 23.</citation>
    <PMID>19549740</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2006</study_first_submitted>
  <study_first_submitted_qc>October 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <results_first_submitted>May 22, 2014</results_first_submitted>
  <results_first_submitted_qc>April 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2017</results_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Janet E. Hall, MD</investigator_full_name>
    <investigator_title>Associate Physician</investigator_title>
  </responsible_party>
  <keyword>Gonadotropin-releasing hormone</keyword>
  <keyword>Estrogens</keyword>
  <keyword>postmenopausal women</keyword>
  <keyword>Pituitary hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>LHRH, N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Arg(5)-Glu(6)-AlaNH2(10)-</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Coded data with identifying information can be requested by contacting the PI.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Younger PMW</title>
          <description>Postmenopausal women (PMW) 45-55 years old receiving the following series of treatments:
A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg.
GnRH doses of 25, 75, 250 and 750 ng/kg given IV every 4 hr
Participants studied at baseline (period 1) and after 1 month of transdermal estrogen 0.05 mg/day (period 2)</description>
        </group>
        <group group_id="P2">
          <title>Older PMW</title>
          <description>Postmenopausal women (PMW) 70-80 years old receiving the following series of treatments:
A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg.
GnRH doses of 25, 75, 250 and 750 ng/kg given IV every 4 hr
Participants studied at baseline (period 1) and after 1 month of transdermal estrogen 0.05 mg/day (period 2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>All Doses of GnRH</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Plus Estrogen</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Estrogen Patch</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>All Doses GnRH</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy postmenopausal women who experienced their last menstrual period a minimum of 12 months previously and met all inclusion and exclusion criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>Younger PMW</title>
          <description>Postmenopausal women (PMW) 45-55 years old receiving the following series of treatments:
A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg.
GnRH doses of 25, 75, 250 and 750 ng/kg given IV every 4 hr
Participants studied at baseline (period 1) and after 1 month of transdermal estrogen 0.05 mg/day (period 2)</description>
        </group>
        <group group_id="B2">
          <title>Older PMW</title>
          <description>Postmenopausal women (PMW) 70-80 years old receiving the following series of treatments:
A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg.
GnRH doses of 25, 75, 250 and 750 ng/kg given IV every 4 hr
Participants studied at baseline (period 1) and after 1 month of transdermal estrogen 0.05 mg/day (period 2)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="2.46"/>
                    <measurement group_id="B2" value="72.8" spread="2.88"/>
                    <measurement group_id="B3" value="61.9" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pituitary Response to GnRH</title>
        <description>Baseline LH and FSH responses to each of 4 GnRH doses - peak to nadir amplitude expressed as percent (%) change from nadir</description>
        <time_frame>Peak hormone level within 2 hours post GnRH doses</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Younger PMW</title>
            <description>Postmenopausal women aged 45-55 years studied at baseline using the following interventions:
A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg.
GnRH doses of 25, 75, 250 and 750 ng/kg given IV every 4 hr</description>
          </group>
          <group group_id="O2">
            <title>Older PMW</title>
            <description>Postmenopausal women aged 70-80 years studied at baseline using the following interventions:
A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg.
GnRH doses of 25, 75, 250 and 750 ng/kg given IV every 4 hr</description>
          </group>
        </group_list>
        <measure>
          <title>Pituitary Response to GnRH</title>
          <description>Baseline LH and FSH responses to each of 4 GnRH doses - peak to nadir amplitude expressed as percent (%) change from nadir</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LH % change: 25 ng/kg GnRH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.88" spread="1.76"/>
                    <measurement group_id="O2" value="6.00" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH % change: 75 ng/kg GnRH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.08" spread="2.94"/>
                    <measurement group_id="O2" value="17.27" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH % change: 250 ng/kg GnRH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.82" spread="12.15"/>
                    <measurement group_id="O2" value="43.96" spread="5.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH % change: 750 ng/kg GnRH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.51" spread="14.17"/>
                    <measurement group_id="O2" value="103.73" spread="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH % change 25 ng/kg GnRH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" spread=".88"/>
                    <measurement group_id="O2" value="4.32" spread=".89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH % change: 75 ng/kg GnRH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.01" spread="1.13"/>
                    <measurement group_id="O2" value="6.98" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH % change: 250 ng/kg GnRH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.57" spread="1.87"/>
                    <measurement group_id="O2" value="9.29" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH % change: 750 ng/kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.55" spread="1.82"/>
                    <measurement group_id="O2" value="17.53" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>null hypothesis will be accepted if there is no difference in the LH response to GnRH as a function of dose in young or old postmenopausal women</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>LH % change with dose</p_value_desc>
            <method>Repeated measures ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>null hypothesis: there will be no difference in the LH and FSH responses to graded doses of GnRH between younger and older postmenopausal women</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>null hypothesis will be accepted if there is no difference in the LH response to GnRH between younger and older postmenopausal women</non_inferiority_desc>
            <p_value>&lt;0.03</p_value>
            <p_value_desc>LH % change with age</p_value_desc>
            <method>Repeated measures ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>null hypothesis will be accepted if there is no difference in the FSH response to GnRH as a function of dose in younger or older postmenopausal women</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>FSH % change with dose</p_value_desc>
            <method>Repeated measures ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>null hypothesis will be accepted if there is no difference in the FSH response to GnRH between young and old postmenopausal women</non_inferiority_desc>
            <p_value>&lt;0.005</p_value>
            <p_value_desc>FSH % change with age</p_value_desc>
            <method>Repeated measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Estrogen on Pituitary Response to GnRH</title>
        <description>LH and FSH responses to each of 4 GnRH doses, expressed as change in amplitude [amp] from peak to nadir between plus estrogen and baseline conditions</description>
        <time_frame>Peak hormone level within 2 hours post GnRH doses</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Young Postmenopausal Women</title>
            <description>Postmenopausal women aged 45-55 years studied after 1 month of transdermal estrogen 0.05 mg/day using the following interventions:
A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg.
GnRH doses of 25, 75, 250 and 750 ng/kg given IV every 4 hr</description>
          </group>
          <group group_id="O2">
            <title>Older Postmenopausal Women</title>
            <description>Postmenopausal women aged 70-80 years studied after 1 month of transdermal estrogen 0.05 mg/day using the following interventions:
A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg.
GnRH doses of 25, 75, 250 and 750 ng/kg given IV every 4 hr</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Estrogen on Pituitary Response to GnRH</title>
          <description>LH and FSH responses to each of 4 GnRH doses, expressed as change in amplitude [amp] from peak to nadir between plus estrogen and baseline conditions</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LH amp change: 25 ng/kg GnRH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="1.9"/>
                    <measurement group_id="O2" value="-0.53" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH amp change: 75 ng/kg GnRH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="3.1"/>
                    <measurement group_id="O2" value="-0.54" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH amp change: 250 ng/kg GnRH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.8" spread="8.0"/>
                    <measurement group_id="O2" value="-5.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH amp change: 750 ng/kg GnRH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.1" spread="18.8"/>
                    <measurement group_id="O2" value="-14.2" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH amp change: 25 ng/kg GnRH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="1.9"/>
                    <measurement group_id="O2" value="-0.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH amp change: 75 ng/kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="7.5"/>
                    <measurement group_id="O2" value="0.21" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH amp change: 250 ng/kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="3.3"/>
                    <measurement group_id="O2" value="-1.9" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FSH amp change: 750 ng/kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.4" spread="3.9"/>
                    <measurement group_id="O2" value="-5.8" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>null hypothesis will be accepted if there is no effect of estrogen on the LH response to GnRH in younger and older postmenopausal women</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>LH amplitude response with estrogen</p_value_desc>
            <method>Repeated measured ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis will be accepted if there is no effect of estrogen on the FSH response to GnRH in younger and older postmenopausal women</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>FSH amplitude response with estrogen</p_value_desc>
            <method>Repeated measures ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis will be accepted if there is no effect of age on the effect of estrogen on the FSH response to GnRH</non_inferiority_desc>
            <p_value>&lt;0.02</p_value>
            <p_value_desc>FSH amplitude response to estrogen with age</p_value_desc>
            <method>Repeated measures ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis will be accepted if there is no effect of age on the effect of estrogen on the LH response to GnRH</non_inferiority_desc>
            <p_value>=0.4</p_value>
            <p_value_desc>LH amplitude response to estrogen with age</p_value_desc>
            <method>Repeated measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Information on AEs was collected for a 3 month period from study entry for each subject.</desc>
      <group_list>
        <group group_id="E1">
          <title>Younger PMW</title>
          <description>Postmenopausal women aged 45-55 years studied at baseline (period 1) and after 1 month of transdermal estrogen 0.05 mg/day (period 2) using the following interventions:
A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg.
GnRH doses of 25, 75, 250 and 750 ng/kg given IV every 4 hr</description>
        </group>
        <group group_id="E2">
          <title>Older PMW</title>
          <description>Postmenopausal women aged 70-80 years studied at baseline (period 1) and after 1 month of transdermal estrogen 0.05 mg/day (period 2) using the following interventions:
A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg.
GnRH doses of 25, 75, 250 and 750 ng/kg given IV every 4 hr</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>New Onset Rapid Atrial Fibrillation</sub_title>
                <description>On admission to Visit #2, subject's heart rate was 155 bpm. EKG revealed subject was in new onset rapid atrial fibrillation. Subject denied symptoms; transferred to a telemetry floor for rate control and discharged 2 days later. PCP notified.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>genital herpes diagnosis</sub_title>
                <description>diagnosis of genital herpes after baseline visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <description>Patient slipped on ice and twisted knee</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No significant limitations were present in this study and the subsequent analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Janet E. Hall</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-877-1112</phone>
      <email>hall.janet@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

